A Blood-Based Proteomic Approach to Stratifying Parkinson’s Disease Subtypes
Personalized briefing
Discovery of the day · Neurology
Proteomics Analysis Identifies Plasma Biomarkers of Glial Activation and Neuronal Health in Parkinson’s Disease
Dear Kelly M Leyden, this is your personalized scientific intelligence briefing — curated for your work in Neurology.
Key finding
Medicine · Neurology · Parkinson’s Disease
Discovery of the day
A targeted proteomics panel in plasma has identified distinct protein signatures linked to glial activation and neuronal integrity that correlate with clinical subtypes and progression in Parkinson’s disease. Researchers quantified over 100 proteins in a well-characterized cohort and found that biomarkers of microglial and astrocytic reactivity, including TREM2 and GFAP, were significantly elevated in patients with faster motor decline and cognitive impairment. For the subscriber focused on blood-based proteomic biomarkers for neurodegenerative diseases, these results demonstrate the potential of plasma assays to stratify patients by disease activity, offering a clinically actionable pathway toward integrating these proteomic measures with imaging and clinical data for personalized monitoring in Parkinson’s disease.
Novelty
88%
Rigor
91%
Significance
95%
Validity
93%
Clarity
90%
Advertisement
ScientificChina — verified Chinese lab & medical equipment suppliers, direct. Browse suppliers →
Update your briefing preferences →
Science Briefing is published by Fountain of Science LLC, Miami, FL.
Your briefing is personalized based on your selected fields, keywords, and research interests.
